Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Revenue (ASC 606) of $2.04 million for fiscal year 2025.
Dianthus Therapeutics, Inc. /DE/ Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $2.04M | -67.3% |
| 2024 | $6.24M | +120.6% |
| 2023 | $2.83M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $396.0K | -81.8% | +105.2% |
| June 30, 2025 | $193.0K | -89.6% | -83.4% |
| March 31, 2025 | $1.16M | +33.1% | -46.5% |
| September 30, 2024 | $2.17M | +135.1% | +16.6% |
| June 30, 2024 | $1.86M | — | +113.2% |
| March 31, 2024 | $874.0K | — | -5.4% |
| September 30, 2023 | $924.0K | -21.2% | -21.2% |
| September 30, 2022 | $1.17M | — | — |
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -67.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Dianthus Therapeutics, Inc. /DE/’s revenue (asc 606) has declined by 28.0% (from $2.83 million to $2.04 million).
- The most recent figure is from Dianthus Therapeutics, Inc. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: